Our consolidated ratios of earnings to fixed charges for each of the periods indicated are as follows:

		For the Six Months Ended June 30, 2010

					For the Years Ended December 31,
					2009		2008			2007			2006			2005
		(dollars in thousands)
Fixed charges:
Interest expense		$	1		$	—	$	1,025		$	8,449		$	11,270		$	15,082
Capitalized interest			8,489			12,339		18,998			14,452			9,162			8,915
Amortization of debt issuance costs			—			—		3,393			3,698			4,208			4,556
Portion of rents representative of the interest factor			13,633			27,267		25,067			24,767			20,300			16,500

	Total fixed charges	$	22,123		$	39,606	$	48,483		$	51,366		$	44,940		$	45,053

Earnings:
Income (loss) before income taxes		$	(200,473	)	$	543,733	$	625,536		$	735,674		$	(52,678	)	$	628,919
Fixed charges per above less capitalized interest			13,634			27,267		29,485			36,914			35,778			36,138
Amortization of capitalized interest			6,387			12,038		9,466			7,625			6,627			5,386
Equity in losses (earnings) equity method investments			1,567			—		(201	)		(7,398	)		(15,705	)		(151	)

	Total earnings, as adjusted	$	(178,885	)	$	583,038	$	664,286		$	772,815		$	(25,978	)	$	670,292

Ratio of Earnings to Fixed Charges(1)			—			14.7		13.7			15.0			—			14.9

(1): The ratio of earnings to fixed charges is not presented for the six months ended June 30, 2010 because in such period fixed charges exceeded earnings by $201.0 million primarily due to a charge of $175.0 million for the upfront disgorgement of past profits recorded in connection with the consent decree we received from the FDA. The ratio of earnings to fixed charges is not presented for the year ended December 31, 2006 because in such period fixed charges exceeded earnings by $70.9 million primarily due to a pre-tax charge of $219.2 million to write off the goodwill for our genetic testing business unit and a pre-tax charge for in-process research and development of $552.9 million incurred in connection with our acquisition of AnorMED, Inc.